Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Lauren Lee, MD, Helene Bruyere, MD, Michael J Barnett, BM, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD, Sujaatha Narayanan, MBBS, Maryse Power, MD, David Sanford, MD, Kevin Song, MD, Heather J. Sutherland, MD PhD, Cynthia L Toze, MD, Jennifer White, MD, Yasser Abou Mourad, MD

Blood (2018) 132 (Supplement 1): 2673.

https://doi.org/10.1182/blood-2018-99-110470

Published: 2018

Journal Articles

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Hatem Alahwal, MPH, MBBS, Heather J. Sutherland, MD PhD, Shruthi Ganeshappa Kodad, MD, Stephen H. Nantel, MD, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Sujaatha Narayanan, MBBS, MRCP, MRCPath, Thomas J. Nevill, MD, Maryse Power, MD, David Sanford, MD, Cynthia L. Toze, MD FRCPC, MSc, Jennifer White, MD, Raewyn Broady, MBChB, Kevin Song, MD

Blood (2018) 132 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2018-99-111533

Published: 2018

Journal Articles

Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival

Ryan J Stubbins, MD MSc, Lauren Lee, MD, Yasser Abou Mourad, MD, Michael J Barnett, BM, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD, Sujaatha Narayanan, MBBS, Thomas J Nevill, MD, Maryse Power, MD, Kevin Song, MD, Heather J. Sutherland, MD PhD, Cynthia L Toze, MD, Jennifer White, MD, David Sanford, MD

Blood (2018) 132 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2018-99-111532

Published: 2018

Journal Articles

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Dennis Dong Hwan Kim, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, Stephen Couban, MDBSc, Robert Delage, MD, Anargyros Xenocostas, MD, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 787.

https://doi.org/10.1182/blood-2018-99-114656

Published: 2018

Journal Articles

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Andrew Wu, BSc, Lin Hanyang, PhD, Katharina Rothe, PhD, Min Chen, MD PhD, Jens Ruschmann, PhD, Oleh Petriv, PhD, Kieran O'Neill, PhD, Tobias Maetzig, MD, David Knapp, PhD, Naoto Nakamichi, MD PhD, Ryan Brinkman, PhD, Inanc Birol, PhD, Donna L Forrest, MD, Carl Hansen, PhD, R. Keith Humphries, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD

Blood (2018) 132 (Supplement 1): 931.

https://doi.org/10.1182/blood-2018-99-113559

Published: 2018

Journal Articles

Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy

Katharina Rothe, PhD, Akie Watanabe, Donna L. Forrest, MD, Sharon Gorski, PhD, Robert Young, PhD, Xiaoyan Jiang, MDPhD

Blood (2018) 132 (Supplement 1): 933.

https://doi.org/10.1182/blood-2018-99-117309

Published: 2018

Journal Articles

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Wasithep Limvorapitak, MD, Michael J Barnett, BM, Donna Hogge, Donna L Forrest, MD, Thomas J Nevill, MD, Sujaatha Narayanan, MBBS, Maryse Power, MB, Stephen H Nantel, MD, Raewyn Broady, MBChB, FRACP, Kevin W Song, MD, Cynthia L Toze, MD, Yasser Abou Mourad, MD, Heather Sutherland, MD, Alina S Gerrie, MD, Jennifer White, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 4544.

https://doi.org/10.1182/blood.V130.Suppl_1.4544.4544

Published: 2017

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries

Christopher M Hillis, MD FRCPC, Lambert Busque, MD PhD FRCPC, Julie Stakiw, MD, Donna L. Forrest, MD FRCPC

Blood (2016) 128 (22): 3079.

https://doi.org/10.1182/blood.V128.22.3079.3079

Published: 2016

Journal Articles

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Musa Alzahrani, MBBS, ABIM, Maryse M Power, MD, Emilie Nevill, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, David Sanford, MD FRCPC, Heather J. Sutherland, MD PhD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Kevin W. Song, MD, Kevin W. Song, MD, Thomas J. Nevill, MD FRCPC, Sujaatha Narayanan

Blood (2016) 128 (22): 4662.

https://doi.org/10.1182/blood.V128.22.4662.4662

Published: 2016

Journal Articles

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Amir Siddiqui, Donna E. Hogge, MD PhD, Thomas J. Nevill, MD, Stephen H. Nantel, MD FRCPC, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Maryse M Power, MD, Kevin W. Song, MD, Cynthia L. Toze, MD MHSc, FRCPC, Yasser Abou Mourad, MD, Heather J. Sutherland, MD PhD, Alina S. Gerrie, MD MPH, FRCPC, David Sanford, MD FRCPC

Blood (2016) 128 (22): 2814.

https://doi.org/10.1182/blood.V128.22.2814.2814

Published: 2016

Journal Articles

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Katie Y. Zhu, BHSc, Kevin W. Song, MD, Joseph M Connors, MD, Tracy Tucker, PhD FCCMG, Graham W. Slack, MD, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, FRCPC, FRCP, FRCPath, Donna L. Forrest, MD FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Thomas J. Nevill, MD FRCPC, Maryse M Power, MB, MRCPI, FRCPath, David Sanford, MD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Heather J. Sutherland, MD PhD FRCPC, Laurie H. Sehn, Raewyn Broady, MBChB, FRACP, Alina S. Gerrie, MD MPH, FRCPC

Blood (2016) 128 (22): 1113.

https://doi.org/10.1182/blood.V128.22.1113.1113

Published: 2016

Journal Articles

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Blood (2016) 128 (22): 5852.

https://doi.org/10.1182/blood.V128.22.5852.5852

Published: 2016

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

NARROW

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only